- Sinclair Pharma said it still expected to post modest annual earnings growth after revenue rose as expected. Sales for the year through December rose by 20% to Â£45.3m, or by 14% on a constant currency basis. "As previously guided, the group expects to deliver a modest Ebitda profit for the year as a whole," the company said. At 9:29am: [ ] Sinclair IS Pharma PLC share price was +1.95p at 23.45p Story provided by StockMarketWire.com
Global aesthetic dermatology firm Sinclair Pharma is forecast to deliver a modest profit. The London-based company saw revenue rise as expected, with sales for the year to December rising by 20% to £45.3m ($62.3m) or by 14% on a constant currency basis. However, its chief executive, Dr David Sinclair, said that while he was pleased with sales, it would not be enough to offset the impact of Brexit and other factors.